Latest Regulatory Approvals News

TPC Consolidated and Wollar Solar have mutually terminated their acquisition agreement after unmet conditions, but both remain open to future partnerships.

SDI Limited reported a modest 2% dip in net profit for H1 FY26 despite a 2.7% rise in sales, driven by growth in aesthetics and exports. The company faces challenges from regulatory bans on Amalgam products while advancing plans for manufacturing upgrades and a potential acquisition.

Beacon Minerals Limited has reported a robust half-year performance with gold sales more than doubling to AU$82.6 million and a comprehensive profit of AU$14.8 million, driven by strong production growth and higher gold prices.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

Insignia Financial Ltd shareholders are invited to vote on a $4.80 per share acquisition scheme by Daintree BidCo, an entity backed by CC Capital Partners LLC and affiliates. The Federal Court has approved the Scheme Meeting and the distribution of the Scheme Booklet, which includes an Independent Expert’s Report supporting the fairness and reasonableness of the offer.

PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Elanor Investors Group reported a $24.5 million net loss for the half year to December 2024, grappling with debt covenant breaches and defaults. The group has struck a $125 million recapitalisation agreement with Rockworth Capital Partners to stabilise its balance sheet and pursue growth.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Bass Oil reported steady January production with a notable regulatory green light for its Vanessa gas field acquisition and a $3.5 million grant to accelerate the Kiwi gas field development.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

FIN Resources has completed the acquisition of the Cabin Lake Gold Project in Canada’s Northwest Territories, securing key permits and preparing for a fully funded drilling campaign starting in March 2026.